FORA Capital’s BeOne Medicines Ltd ONC Stock Holding History

FORA Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,171	Closed	-$425K	–	493
2021 Q3	$425K	Buy	+1,171	New	+$383K	0.11%	229
2020 Q3	–	Sell	-3,211	Closed	-$605K	–	1041
2020 Q2	$605K	Buy	+3,211	New	+$523K	0.21%	130
2020 Q1	–	Sell	-3,188	Closed	-$528K	–	1402
2019 Q4	$528K	Buy	+3,188	New	+$530K	0.05%	377

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

FORA Capital's ONC Position: Q4 2021 in Review

FORA Capital sold out of BeOne Medicines Ltd (ONC) in Q4 2021, closing a stake of 1,171 shares — an estimated $425K sold.

FORA Capital first reported a position in ONC in Q4 2019 and held it in 3 quarters. The position peaked at $605K in Q2 2020. 262 funds tracked by Wall St. Rank hold ONC as of Q4 2021.

FORA Capital reported no remaining BeOne Medicines Ltd position as of Q4 2021 after selling out during the quarter.
FORA Capital sold 1,171 BeOne Medicines Ltd shares in Q4 2021, an estimated $425K.
FORA Capital first reported a position in BeOne Medicines Ltd in Q4 2019 and held it in 3 quarters.
FORA Capital's BeOne Medicines Ltd position peaked at $605K in Q2 2020.
262 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2021.

Based on FORA Capital's 13F filing for Q4 2021, filed 11 Feb 2022.